Bloomberg Daybreak: Asia Edition Japan's Takaichi Formally Elected PM, Stocks Get Tech Boost
Feb 19, 2026
Tim Pagliara, CIO at CapWealth, gives market and macro color on AI disruption, Fed moves and US economic data. Toru Yoshimura, Senior Executive Officer at Kirin, outlines Kirin’s pivot from beer to health sciences, global brand plays and Asia-first expansion. They discuss tech-driven stock rebounds, AI’s impact on software pricing, and science-led product rollouts in Asia and beyond.
AI Snips
Chapters
Transcript
Episode notes
Asia First, Science-Backed U.S. Strategy
- Kirin focuses first on Asia-Pacific, especially Southeast Asia and China, while treating the U.S. as strategic but hard to enter.
- They plan a credibility-first U.S. push grounded in proprietary ingredients like LC-Plasma and acetylcholine.
Proprietary Ingredients Drive Credibility
- Kirin's proprietary ingredients include LC-Plasma for immune activation and acetylcholine for cognition.
- They already sell acetylcholine in the U.S. through their biochemical unit as evidence of scientific foothold.
Production And Cross-Border Sales Approach
- Kirin currently produces all health products in Japan or Australia and sells mainly via e-commerce and cross-border channels.
- Local production in China is considered later once scale and regulatory clarity justify it.